This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

The present invention provides novel crystalline forms of apremilast hemitoluene solvate, apremilast hydrate, and apremilast anhydrate and an amorphous form of apremilast, and processes for the preparation of these forms.

The present invention provides novel crystalline forms of apremilast hemitoluene solvate, apremilast hydrate, and apremilast anhydrate and an amorphous form of apremilast, and processes for the preparation of these forms.

The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, ##STR00001## where in the formula, the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at positions 5,6 and 13,14 they may be in cis or in trans orientation, Q stands for a hydroxyl-group and Z stands for a hydroxyl- or oxo-group, R.sup.1 and R.sup.2 independently represent hydrogen atom or a straight or branched C.sub.1-10 alkyl- or aralkyl-group, optionally substituted with ONO.sub.2 group, or an aralkyl- or aryl-group, which contains heteroatom, R.sup.3 represents a straight or branched, saturated or unsaturated C.sub.4-6 hydrocarbon group, or a C.sub.4-10 alkylcycloalkyl- or cycloalkyl-group, or an optionally with alkyl group or halogen atom substituted phenyl-, C.sub.7-10 alkylaryl- or hetaryl-group, Y represents (CH.sub.2).sub.n group or O atom or S atom, and where n=0-3.

The subject of the invention is process for the preparation of the prostaglandin amides of the general formula I, ##STR00001## where in the formula, the bonds marked with dotted lines may be single or double bonds, in the case of double bounds at positions 5,6 and 13,14 they may be in cis or in trans orientation, Q stands for a hydroxyl-group and Z stands for a hydroxyl- or oxo-group, R.sup.1 and R.sup.2 independently represent hydrogen atom or a straight or branched C.sub.1-10 alkyl- or aralkyl-group, optionally substituted with ONO.sub.2 group, or an aralkyl- or aryl-group, which contains heteroatom, R.sup.3 represents a straight or branched, saturated or unsaturated C.sub.4-6 hydrocarbon group, or a C.sub.4-10 alkylcycloalkyl- or cycloalkyl-group, or an optionally with alkyl group or halogen atom substituted phenyl-, C.sub.7-10 alkylaryl- or hetaryl-group, Y represents (CH.sub.2).sub.n group or O atom or S atom, and where n=0-3.

This document discloses molecules having the following formula (Formula One):

##STR00001##

and processes associated therewith.

This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

This document discloses molecules having the following formula (Formula One): ##STR00001##
and processes associated therewith.

The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).

##STR00001##